Washington, D.C.—A Utah Senate Committee passed a resolution urging Congress and the President to “act quickly to protect American consumers” by requiring the FDA to “issue product quality and safe consumption guidelines for cannabidiol (CBD) products,” according to a press release from the Natural Products Association (NPA).

NPA worked with lawmakers in Utah to pass the resolution, and is continuing to work with Congress to pass legislation to set a safe level of consumption for CBD. The U.S. Senate is currently considering legislation passed by the House of Representatives that would appropriate $100,000 for the FDA to perform a Health Hazard Evaluation and set a safe level of CBD for consumers to use each day.
Related: NJ Senate Passes Resolution Asking Congress for Safe CBD Legislation NJ Senate Introduces Bill Giving CBD Businesses Access to Financial Services FDA Releases Statement Regarding CBD; Industry Reacts
Daniel Fabricant, Ph.D., President and CEO of NPA, said in the release: “The states are starting to take action to regulate the growing CBD marketplace but unless we get clear federal guidelines and safety standards consumers are still going to be at risk. Each day Congress allows these products to go unregulated elevates the risk of a public health crisis. Inaction from the FDA is bad for public health, bad for the benefits CBD offers and bad for the hemp industry’s growth and job-creating potential.”
Related: Phytocannabinoids: 25 Things to Know Now Selling CBD: 7 Qs Retailers Should Be Asking